RxDoctor Payments Data

Tanya Kirpalani, PA

Medical · Clermont, FLNPI 1982993143

Payments from drug & device makers

$9,175in general payments, 2019–2025

Across 492 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$673
  • Bayer$509
  • Amgen$444
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,10999%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,175 in reported general payments places this provider in the 90th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$45,448
Medicare patients
154
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$60,890
MounjaroTirzepatide52$56,989
JardianceEmpagliflozin37$33,897
RybelsusSemaglutide13$29,677
FarxigaDapagliflozin Propanediol28$24,680
TrulicityDulaglutide13$20,248
Xigduo XrDapaglifloz Propaned/Metformin18$15,926
Synjardy XrEmpagliflozin/Metformin Hcl20$14,815
EliquisApixaban14$12,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,252
Breo ElliptaFluticasone/Vilanterol15$10,081
EntrestoSacubitril/Valsartan11$8,393
SymbicortBudesonide/Formoterol Fumarate15$3,442
Omeprazole187$2,963
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,227$90,56871 claims
Lilly USA, LLCMounjaro, Trulicity$673$77,23765 claims
Boehringer IngelheimJardiance, Synjardy Xr$271$48,71257 claims
AstraZenecaFarxiga, Symbicort$1,056$28,12243 claims
GSKTrelegy Ellipta, Breo Ellipta$228$22,33334 claims
PfizerEliquis$231$12,31114 claims
NovartisEntresto$73$8,39311 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$1,450157 claims
AbbVieSynthroid$1,207$1,10320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,031 medical providers in Florida.

Other medical in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →